Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Smallcap 250 and 6.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences reported consolidated revenue from operations of Rs 807.47 crore for Q3 FY26, up about 11% YoY from Rs 727.45 crore. Net profit for the quarter rose nearly 25% YoY to Rs 108.83 crore, while nine-month net profit grew 35% YoY to Rs 368.40 crore. Operating margin expanded to 26.17% in Q3 from 23.85% a year ago, and net profit margin improved to 13.48% from 11.97%. The company booked a one-time exceptional charge of Rs 17.24 crore (consolidated) related to new Labour Codes, which raised gratuity and leave liabilities. Prior period numbers were restated to reflect the final purchase price allocation for the Swiss Parenterals acquisition. The auditor changed mid-year from Deloitte Haskins & Sells to Walker Chandiok & Co LLP, which issued an unmodified review opinion.
Strong double-digit profit growth and improving margins are positives for shareholders, though the exceptional charge and restated comparables may cause some one-time noise. Post-quarter, Swiss Parenterals became a wholly owned subsidiary via a share swap, which should support future consolidated earnings.